[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diet-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diet-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,89,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100423855","phase-1-developing-biomarkers-of-dietary-intake-dose-dependent-measurement-of-sugar-intake-100423855",false,"NCT04799301","Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Body mass index less than or equal to 35 kg\u002Fm\\^2 to minimize the impact of body size on isotope measurements.\n* Women and men between the ages of 18-65 years will be recruited for this study\n* Healthy, as determined by medical history, physical examination, and laboratory tests.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Fasting plasma glucose greater than or equal to 126 mg\u002FdL\n* Alopecia totalis or inability to grow hair (at least one inch of hair required to obtain sample)\n* Use of medication affecting metabolism and appetite in the last three months\n* Medically- or self-imposed dietary restrictions that would limit a participant s ability\u002Fwillingness to consume the diet to which they are randomized\n* Current pregnancy, pregnancy within the past 6 months or currently lactating\n* History or clinical manifestations of acute or chronic disorders or conditions that may affect appetite or EE, (such as, but not limited to type 1 or type 2 diabetes, Cushing s disease, thyroid disorders, coccidiomycoses)\n* Gastrointestinal disease, including inflammatory bowel diseases (e.g. Chron s disease and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer (active) which may alter metabolism or absorption of study food\n* Current, unstable medical conditions such as hepatitis, renal insufficiency, cancer requiring treatment in the last 5 years (except for nonmelanoma skin cancers or cancers that have clearly been cured), or central nervous system disorders etc. as assessed by history and physical exam\n* Diagnosis of binge eating disorder, anorexia-nervosa, or bulimia-nervosa\n* Evidence of alcohol abuse as defined by greater than or equal to 8-point score on the Alcohol consumption screening AUDIT questionnaire in adults\n* Current use of tobacco products that exceed Low Dependence on the Fagerstrom Test for Nicotine Dependence Tool (score greater than 2)\n* Current use of drugs such as amphetamines, cocaine, or heroin\n* Any condition not specifically mentioned above that, in the opinion of the investigator, may interfere with the study or prove unsafe for participation.\n* Weight change of plus or minus 5% in the last 3 months, per self report.\n* Non-English speaking\n* Inability of participant to understand and the unwillingness to sign a written informed consent document.\n\nConditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the investigators. Additionally, potential subjects might be excluded if they demonstrate a style of interpersonal relationships that would inhibit successful completion of the study.\n\nNon-English-speaking subjects as a population will be excluded from participation in this protocol. One of the secondary hypotheses of the protocol relates to a battery of psychological questionnaires and performances tests which are administered to the volunteers at the beginning and end of the study. There are currently no validated, translated forms of these questionnaires and tests available; therefore, we will restrict enrollment to English speaking subjects only.",true,"ALL","18 Years","65 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Background:\n\nDiet is one of the most modifiable behaviors affecting health. But diet assessment measures that are based on self-report can be inaccurate. Researchers want better ways to address the role of diet in chronic disease. They want to see if stable isotopes can be used to better assess what people eat.\n\nObjective:\n\nTo see if stable isotopes can help scientists identify things people eat.\n\nEligibility:\n\nHealthy adults ages 18 to 65\n\nDesign:\n\nParticipants will be screened with a medical history and physical exam. They will have blood and urine tests. These tests will be repeated during the study.\n\nParticipants will stay in the inpatient unit of the NIH in Phoenix, Arizona, for 13 weeks.\n\nFor 7 days, participants will eat a diet prepared by the NIH kitchen. They will get balanced meals that are 50% carbohydrates, 20% protein, and 30% fat. Then participants will be randomly placed on one of 3 diets containing different percentages of carbohydrates from soda.\n\nParticipants height and weight will be measured. The amount of fat and muscle in their body will be measured by body scans that are similar to x-rays.\n\nParticipants will have oral glucose tolerance tests. They will consume a sugar drink and then give blood samples over 3 hours.\n\nParticipants will give hair and stool samples.\n\nParticipants will complete a diet questionnaire. It assesses their food intake over 24 hours.\n\nParticipants will complete behavioral questionnaires and computer performance tests.\n\nParticipants will have fat biopsies taken from their stomach and thigh.\n\nParticipants will have three 24-hour stays in a metabolic chamber. It is used to measure metabolism.",[27,28],"Diet Therapy","Healthy Volunteers",[30,31,32],"Biomarkers","Stable Isotopes","Dietary Intake","RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-18","ACTUAL",{"date":39,"type":37},"2022-02-23",{"date":41,"type":21},"2028-01-01",{"name":43,"class":44},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":73,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":45},"100622820","soluble-and-osmotic-fibre-solos-diet-for-constipation-100622820","NCT07388589","Soluble and Osmotic Fibre (SOLOS) Diet for Constipation","The Soluble and Osmotic Fibre (SOLOS) Diet for Functional Bowel Disorders With Constipation","SOLOS","Inclusion Criteria:\n\n* Presented with symptoms of FC, IBS-C, or SIBO-C\n* Were aged 18 to 70 years old. (Research focus is on adult patients, excluding older adults and children)\n* Date of baseline (first) and follow-up appointments ranged from January 2021 to December 2025\n* Did not attend follow-up appointments (Data would be treated as \"intention to treat\" and data points were carried forward for conservative analysis).\n\nExclusion Criteria:\n\n* Had no history of constipation-related symptoms (Does not relate to research question's population or outcome)\n* Started treatment before January 2021\n* Were not due for follow-up before the end of December 2025\n* Symptom and stool data inadequately recorded","70 Years",{"count":56,"type":21},180,"OBSERVATIONAL","This research aims to study the dual effectiveness of incorporating soluble fibre and osmotic carbohydrates (SOLOS), with or without restricting fructans and GOS, and present novel findings in managing GI symptoms in patients with functional bowel disorders with constipation. These findings may also support researchers and clinicians in shaping new dietary approaches in the management of general constipation symptoms.",[60,61,62,63,64,65,66,67,27,68,69,70,71,72],"Constipation","Constipation - Functional","Constipation Chronic Idiopathic","Constipation Predominant Irritable Bowel Syndrome","Constipation, Signs and Symptoms, Digestive","Constipation-predominant IBS (IBS-C)","Constipation-predominant Irritable Bowel Syndrome","Constipation-predominant Irritable Bowel Syndrome (IBS-C)","Diet Modification","Diet, Food and Nutrition","Dietary and Nutritional Therapies","Dietary Fiber","Dietary Fibers",[60,74,75,76,77],"Functional constipation","Constipation-predominant irritable bowel syndrome (IBS-C)","Soluble fiber","osmotic sugar","NOT_YET_RECRUITING","2026-02-04",{"date":81,"type":37},"2026-02-06",{"date":83,"type":21},"2026-02-02",{"date":85,"type":21},"2027-03-01",{"name":87,"class":88},"Singapore Institute of Technology","OTHER",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":45},"100589390","phase-2-comparison-of-quality-of-life-during-a-flare-of-crohns-disease-treated-with-prednisolone-or-acded-with-pen-in-adult-patients-100589390","NCT06953791","Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Patients","Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Standard of Care or an Adapted Crohn's Disease Exclusion Diet With Partial Enteral Nutrition in Adult Patients","CONSISTENT","Inclusion Criteria:\n\n* Must be ≥ 18 years at the time of signing the informed consent.\n* Macroscopic small bowel involvement, or isolated large bowel disease confined to the right or transverse colon confirmed by endoscopy\n* Patients with a Crohn's disease activity index (CDAI) of ≥ 150\n* Patients will not be excluded if they have received 5ASA or an immunomodulator for \\> 8 weeks and the dose is stable, or if they start a thiopurine concurrently, as thiopurines are not considered sufficient to induce remission in active disease before 8 weeks as an isolated therapy\n* Understand and voluntarily sign an informed consent document prior to any study related assessments\u002Fprocedures\n* Able to adhere to the study visit schedule and other protocol requirements\n* All subjects must agree to refrain from donating blood while on study drugs\n* All subjects must agree not to share medication.\n* Subject (male or female) is willing to use highly effective contraceptive methods during treatment and for 28 days (male or female) after the end of treatment\n\nExclusion Criteria:\n\n* Patients with with minimal disease activity (CDAI \\\u003C150) or severe disease (CDAI \\>450)\n* Patients who have received corticosteroids of any kind in the previous 4 weeks\n* Patients who have started an immunomodulator in the previous 8 weeks\n* Any current biological or small molecule treatment\n* Isolated large bowel disease iinvolving the recto-sigmoid or descending colon\n* Patients with penetrating disease (abscess or fistula)\n* Active perianal disease\n* Fixed stricture or small bowel obstruction\n* Normal fecal calprotectin\n* Active extraintestinal disease (e.g. joint disease)\n* Patients who have undergone an intestinal resection\n* Sclerosing cholangitis\n* History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.\n* Women during pregnancy and lactation Participation in other clinical trials or observation period of competing trials.",{"count":98,"type":21},52,[100],"PHASE2","Crohn's disease (CD), a type of inflammatory bowel disease (IBD), is on the rise globally. Although medical treatments have advanced, CD still leads to significant health issues due to disease progression and medication side effects. Exclusive enteral nutrition (EEN) is a recommended first-line treatment for pediatric CD, proving more effective than oral corticosteroids without side effects. However, EEN demands strict adherence, making it challenging for patients, particularly adults.\n\nIn 2019, Levine et al. found that a combination of a specific diet (CD exclusion diet, CDED) and partial enteral nutrition (PEN) was as effective as EEN in inducing remission in pediatric patients, with better tolerance and adherence. CDED focuses on whole foods and aims to minimize harmful dietary components affecting the gut.\n\nIn clinical practice, an adapted CDED (aCDED) has been used to provide more food choices, but it lacks validation in clinical trials. An aCDED that considers regional and seasonal food variations could enhance patient adherence and align with modern dietary preferences.\n\nThis study aims to compare the quality of life during a flare up of Crohn's disease treated with standard of care or an adapted Crohn's disease exclusion diet with partial enteral nutrition in adult patients.",[103,104,27],"Crohn Disease","Nutrition Assessment",[106,107,108,109],"Nutrition","crohn disease","diet therapy","consistent",{"date":111,"type":37},"2026-02-05",{"date":113,"type":37},"2026-02-01",{"date":115,"type":21},"2028-02-01",{"name":117,"class":88},"University Hospital Tuebingen",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":45},"100611239","protein-supplementation-during-dialysis-prosed-100611239","NCT07237997","Protein Supplementation During Dialysis (PROSED)","Re-examining Nutrition in Dialysis Patients: Nutritional Losses and the Role of Supplementation (Part 2).","PROSED","Inclusion Criteria:\n\n* Age ≥ 18 years (no upper age limit)\n* Patients receiving maintenance dialysis for ≥ three months\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Anticipated live donor kidney transplant and\u002For kidney recovery within the period of sample collection.\n* Anticipated change of dialysis modality within the period of sample collection\n* Severe malnutrition based on either:\n\n  * Renal 7-point Subjective Global Assessment (SGA) scores of 1-2\n  * Global Leadership Initiative Malnutrition (GLIM) Stage 2\n* Protein-losing enteropathy.\n* Persistent nephrotic syndrome with \\>3g\u002Fday urinary protein loss.\n* Active wounds or burns contributing to protein losses as judged by the investigator.\n* Current active acute inflammatory illness (likely to have catabolic effect in the opinion of the investigator).\n* Current malignancy based on recent (\\\u003C12 months) diagnosis and\u002For active treatment for malignancy and\u002For planned treatment for malignancy, excluding non-melanoma skin cancers.\n* Pregnancy (current or planned within duration of study) or breast feeding.\n* People with swallowing difficulties precluding safe ingestion (International Dysphagia Diet Standardization Initiative (IDDSI) level 0 thin fluid).\n* People receiving intradialytic parenteral nutrition or intra-peritoneal amino acids, or any other forms of artificial feeding\n* People prescribed levodopa\n* People who are receiving chronic glucocorticoid therapy (\\>10mg day prednisolone or equivalent for \\>7 days within preceding 90 days).\n* People who are consuming a protein dietary intake above 1.5g protein\u002Fkg\u002Fbody weight.\n* People who, in the opinion of the investigator, will be unable to comply with study protocol requirements.\n* People who are vegan or other religious based dietary restrictions which would prevent them taking the supplement.",{"count":127,"type":21},114,[129],"NA","When a patient has dialysis some nutrients are lost in the process. Nutritional losses include protein, trace elements (i.e. zinc, copper and selenium) and water-soluble vitamins (Vitamins C and B). These nutrients are essential for normal body function, including a good immune system and nutritional status. For example, on average the protein losses during a dialysis session (the process where the blood is cleaned via a machine and special fluid) is equal to 6g of protein\u002Fday (which is the equivalent of the amount of protein in 1 egg). Protein needs for the general population are 0.8g protein per kg of body weight. Because people on dialysis lose protein via the dialysis, it is thought that these people need to eat more protein. Currently, in clinical practice for people receiving dialysis, the guidelines are to aim for 1.1 -1.4g of protein per kg of body weight. However, the research is old and very weak.\n\nDialysis treatments have changed over the past 40 years, and the investigator does not know if the replacement of these nutritional losses is important to how well people do on dialysis and if they have any effect on survival. Previous research is mostly limited to haemodialysis (a type of dialysis that requires a machine which cleans the patients' blood via special filters) and peritoneal dialysis (this is a type of dialysis which happens via the patients' tummy). There is no research on the nutritional supplementation in home HD and nocturnal HD. Our research will investigate if a higher protein provision leads to a reduction is hospital admissions and improved outcomes in patients receiving dialysis.",[132,133,134,135,136,137,27,138,139,140],"Dialysis Patients","Dialysis","Protein Energy Wasting","Protein Intake","High Protein Dietary Intake","Diet","Hospitalisation","Muscle Mass and Strength","Muscle Mass","2025-11-14",{"date":143,"type":37},"2025-11-20",{"date":145,"type":21},"2026-01-05",{"date":147,"type":21},"2029-10-30",{"name":149,"class":88},"University of Nottingham"]